(1) Background:NF2-related schwannomatosis, characterized by the development of bilateral vestibular schwannomas, often necessitates varied treatment approaches. Bevacizumab, though widely utilized, demonstrates variable effectiveness on hearing and tumor growth. At the same time, (serious) adverse events have been frequently reported. (2) Methods: A single center retrospective study was conducted, onNF2-related schwannomatosis patients treated with bevacizumab from 2013 to 2023, with the aim to assess treatment-related and clinical outcomes. Outcomes of interest comprised hearing, radiologic response, symptoms, and adverse events. (3) Results: Seventeen patients received 7.5 mg/kg bevacizumab for 7.1 months. Following treatment, 40% of the patients experienced hearing improvement, 53%, stable hearing, and 7%, hearing loss. Vestibular schwannoma regression occurred in 31%, and 69% remained stable. Further symptomatic improvement was reported by 41%, stable symptoms by 47%, and worsened symptoms by 12%. Treatment discontinuation due to adverse events was observed in 29% of cases. Hypertension (82%) and fatigue (29%) were most frequently reported, with no occurrences of grade 4/5 toxicities. (4) Conclusion: Supporting previous studies, bevacizumab demonstrated positive effects on hearing, tumor control, and symptoms inNF2-related schwannomatosis, albeit with common adverse events. Therefore, careful consideration of an appropriate management strategy is warranted.
（1）背景：以双侧前庭神经鞘瘤为特征的NF2相关神经鞘瘤病常需采用多种治疗策略。贝伐珠单抗虽广泛应用，但其对听力和肿瘤生长的疗效存在差异，同时（严重）不良事件频发。（2）方法：本研究对2013年至2023年间接受贝伐珠单抗治疗的NF2相关神经鞘瘤病患者开展单中心回顾性分析，旨在评估治疗相关及临床结局。观察指标包括听力状况、影像学反应、症状变化及不良事件。（3）结果：17例患者以7.5 mg/kg剂量接受贝伐珠单抗治疗，中位疗程7.1个月。治疗后40%患者听力改善，53%保持稳定，7%出现听力下降。前庭神经鞘瘤体积缩小者占31%，69%保持稳定。症状改善、稳定及加重者分别占41%、47%和12%。29%病例因不良事件终止治疗，其中高血压（82%）和疲劳（29%）最为常见，未发生4/5级毒性反应。（4）结论：本研究验证了既往研究结果，贝伐珠单抗对NF2相关神经鞘瘤病的听力、肿瘤控制及症状改善具有积极作用，但不良事件发生率较高，因此需审慎制定个体化管理策略。
Bevacizumab Treatment for Patients withNF2-Related Schwannomatosis: A Single Center Experience
肿瘤(癌症)患者之家